Validea Detailed Fundamental Analysis

Validea's guru fundamental report rates Thermo Fisher Scientific Inc. (TMO), a large-cap medical equipment and supplies growth stock, at 77% using the Partha Mohanram P/B Growth Investor model. This model, developed by academic Partha Mohanram and known for identifying sustained growth in low book-to-market stocks, indicates potential interest in TMO, though it is just below the 80% threshold Validea defines as 'some interest'.

Analysis

Thermo Fisher Scientific Inc. (TMO) scores a 77% rating based on Validea's P/B Growth Investor model, which is derived from the academic work of Partha Mohanram. This model is designed to identify low book-to-market stocks with strong prospects for sustained growth. While the 77% score is positive, it falls just short of the 80% threshold that Validea considers indicative of 'some interest.' The analysis reveals that TMO passes a majority of the model's fundamental tests, demonstrating strength in its low book-to-market ratio, return on assets (ROA), and cash flow from operations relative to assets. Furthermore, the company exhibits stability, passing on low variance in both ROA and sales. However, the model flagged two specific weaknesses: TMO failed the criteria for Advertising to Assets and Research and Development to Assets. For a large-cap company in the Medical Equipment & Supplies industry, a failure on the R&D metric may warrant particular attention, as it could imply lower relative investment in future innovation compared to the model's benchmark.

Key Decisions for Investors

• Given that TMO passes most fundamental criteria related to profitability and stability, existing investors may find the analysis supportive of a hold strategy, though the sub-80% score tempers a strong bullish conviction.
• Potential investors should conduct further due diligence on TMO's R&D and advertising expenditures to assess whether the low ratios are a sign of capital efficiency or a potential risk to long-term competitive positioning.
• The 77% score from this specific growth model should be treated as a single data point; it is advisable to weigh these findings against other quantitative models and qualitative industry analysis before making a capital allocation decision.